Star Scientific Takes a Magical Mulligan On Failed Study Results
GLEN ALLEN, Va. (TheStreet) --Did Star Scientific (STSI) release materially false information to investors this week when it announced results from a study of its dietary supplement Anatabloc?
In a statement of correction issued Friday, Star Scientific claims to have "underreported" results from a phase II study investigating the effect of Anatabine on C-reactive protein (CRP), a biomarker for inflammation.
On Wednesday, Star Scientific said CRP levels dropped in 26% of diabetic patients taking Anatabloc for a month. On Friday, however, the company claimed CRP levels had actually dropped in 61% of diabetic patients.
Star Scientific's performed the same magical upsizing on results for the non-diabetic patients in the study, with CRP responses improving from 12% on Wednesday to 38% on Friday.
The company offered no explanation Friday for how or why the data from the study allegedly improved over the course of two days. Without an explanation, it's impossible to know which data are false and which are true. Let's hope someone at the Securities and Exchange Commission gets some answers. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuersteinSelect the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
